Home › Companies › BLUEPRINT MEDICINES CORP. › 2023-2024

BLUEPRINT MEDICINES CORP. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and BLUEPRINT MEDICINES CORP.’s Form 8-K, filed 2024-06-14 (Item 5.07 on EDGAR). Page generated 02 October 2026.

9Reported items
310Asset managers
3,417Fund votes
2024-06-12Meeting date

Proxy season: 2023-2024 2024-2025

Explore BLUEPRINT MEDICINES CORP. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by BLUEPRINT MEDICINES CORP.

These tallies are BLUEPRINT MEDICINES CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-14 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BLUEPRINT MEDICINES CORP. — official shareholder meeting results, meeting held 2024-06-12
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Daniella Beckman	54,014,668	--	--	4,259,561	2,067,113	Majority: yes
Elect Director: Habib Dable	40,783,723	--	--	17,490,506	2,067,113	Majority: yes
Elect Director: Lynn Seely, M.D.	42,706,299	--	--	15,567,930	2,067,113	Majority: yes
Proposal 3: The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders' non-binding, advisory vote with respect to compensation paid to the Company's named execut	56,844,879	1,345,313	84,037	--	2,067,113	Majority: yes
4. The Company's stockholders approved the 2024 Plan.	41,494,784	16,766,684	12,761	--	2,067,113	Majority: yes
5. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2024.	60,124,981	198,317	18,044	--	--	Majority: yes

Source: BLUEPRINT MEDICINES CORP., Form 8-K, filed with the SEC on 2024-06-14 — read the filing on EDGAR.

How asset managers voted at the BLUEPRINT MEDICINES CORP. 2023-2024 meeting

Each item below shows how the 310 asset managers that disclosed a BLUEPRINT MEDICINES CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BLUEPRINT MEDICINES CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 11 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 56,844,879AGAINST: 1,345,313

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Proposal 3: The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders' non-binding, advisory vote with respect to compens”): 56,844,879 for, 1,345,313 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,616,902 outstanding shares: 91% for, 2% against (93% of the company cast a for/against vote).

The 301 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 98%

FOR: 97.9%AGAINST: 2.0%ABSTAIN: 0.1%NOT VOTED: 0.0%ONE YEAR: 0.0%

Largest asset managers voting on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset manager	For	Against	Vote
T. Rowe Price	12,456,846	0	For
Fidelity	11,130,535	0	For
Vanguard	9,000,829	0	For
BlackRock	5,394,909	0	For
Wellington	3,861,287	0	For
Man Group plc	3,000,550	0	For
State Street	2,806,554	0	For
Rock Springs Capital Management LP	2,498,449	0	For
New York Life	2,083,324	0	For
JPMorgan	1,831,909	0	For
AllianceBernstein	1,514,617	0	For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	1,472,544	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,351,661	0	For
PICTET ASSET MANAGEMENT SA	1,316,863	0	For
LORD, ABBETT & CO. LLC	1,240,696	0	For
Lord Abbett	1,145,420	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	1,143,760	0	For
American Century	1,062,683	0	For
Charles Schwab	1,025,128	0	For
Delaware/Macquarie	945,166	0	For
Invesco	0	944,848	Against
Woodline Partners LP	909,910	0	For
Polar Capital Holdings Plc	865,000	0	For
BROWN ADVISORY INC	566,454	0	For
Northern Trust	550,751	42	For

Showing the 25 largest of 301 asset managers. See all 301 in the interactive database.

2. APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 6 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 82%1 YEAR 16%

The 293 asset managers below cast 100% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR: 0.7%ABSTAIN: 0.0%ONE YEAR: 82.0%1 YEAR: 16.4%3 YEARS: 0.7%THREE YEARS: 0.1%1-YEAR: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO ” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
T. Rowe Price	0	0	0	0	One Year
Fidelity	0	0	0	0	One Year
Vanguard	0	0	0	0	One Year
BlackRock	0	0	0	0	One Year
Wellington	0	0	0	0	1 Year
Man Group plc	0	0	0	0	1 Year
State Street	0	0	0	0	One Year
Rock Springs Capital Management LP	0	0	0	0	One Year
New York Life	0	0	0	0	One Year
AllianceBernstein	0	0	0	0	One Year
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	0	0	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
PICTET ASSET MANAGEMENT SA	0	0	0	0	One Year
LORD, ABBETT & CO. LLC	0	0	0	0	One Year
Lord Abbett	0	0	0	0	One Year
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	0	0	0	0	One Year
American Century	0	0	0	0	One Year
Charles Schwab	0	0	0	0	1 Year
Delaware/Macquarie	0	0	0	0	One Year
Invesco	0	0	0	0	One Year
Woodline Partners LP	0	0	0	0	One Year
Polar Capital Holdings Plc	0	0	0	0	One Year
JPMorgan	0	0	0	0	1 Year
BROWN ADVISORY INC	0	0	0	0	One Year
Northern Trust	0	0	0	0	1 Year

Showing the 25 largest of 293 asset managers. See all 293 in the interactive database.

3. APPROVAL OF THE BLUEPRINT MEDICINES CORPORATION 2024 STOCK INCENTIVE PLAN.

COMPENSATIONMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%AGAINST 29%

FOR: 41,494,784AGAINST: 16,766,684

BLUEPRINT MEDICINES CORP.’s own tally for this item (“4. The Company's stockholders approved the 2024 Plan.”): 41,494,784 for, 16,766,684 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,616,902 outstanding shares: 66% for, 27% against (93% of the company cast a for/against vote).

The 101 asset managers below cast 81% of the shares they voted on this item FOR (27,872,885 for, 6,540,409 against).

FOR 81%AGAINST 19%

FOR: 27,872,885 (81.0%)AGAINST: 6,540,409 (19.0%)

Largest asset managers voting on “APPROVAL OF THE BLUEPRINT MEDICINES CORPORATION 2024 STOCK INCENTIVE PLAN.” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset manager	For	Against	Vote
Vanguard	8,825,344	0	For
Fidelity	6,004,519	0	For
T. Rowe Price	5,448,322	0	For
BlackRock	3,279,222	0	For
Lord Abbett	0	1,145,420	Against
Delaware/Macquarie	0	945,166	Against
State Street	870	821,053	Against
JPMorgan	724,726	0	For
American Century	0	519,467	Against
Charles Schwab	502,210	0	For
Invesco	0	430,463	Against
AllianceBernstein	428,993	0	For
WILLIAM BLAIR FUNDS	0	350,924	Against
Principal	199,975	76,749	For
Equitable	261,823	0	For
TIAA	261,525	0	For
MUTUAL FUND SERIES TRUST	231,685	0	For
Hartford	222,884	0	For
Jackson National	0	221,771	Against
Manager Directed Portfolios	212,314	0	For
AB DISCOVERY GROWTH FUND, INC.	202,784	0	For
Brown Advisory Funds	0	201,802	Against
John Hancock	109,582	84,418	For
Goldman Sachs	0	178,055	Against
Brighthouse	37,202	139,302	Against

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

4. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 60,124,981AGAINST: 198,317

BLUEPRINT MEDICINES CORP.’s own tally for this item (“5. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2024.”): 60,124,981 for, 198,317 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,616,902 outstanding shares: 96% for, 0.4% against (96% of the company cast a for/against vote).

The 100 asset managers below cast 99.9% of the shares they voted on this item FOR (34,394,142 for, 349 against).

FOR 99.9%

FOR: 34,394,142 (99.9%)AGAINST: 349 (0.0%)ABSTAIN: 17,858 (0.1%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	8,825,344	0	0	For
Fidelity	6,004,519	0	0	For
T. Rowe Price	5,448,322	0	0	For
BlackRock	3,279,222	0	0	For
Lord Abbett	1,145,420	0	0	For
Delaware/Macquarie	945,166	0	0	For
State Street	821,787	136	0	For
JPMorgan	724,726	0	0	For
American Century	519,467	0	0	For
Charles Schwab	502,210	0	0	For
Invesco	430,463	0	0	For
AllianceBernstein	428,993	0	0	For
WILLIAM BLAIR FUNDS	350,924	0	0	For
Principal	276,724	0	0	For
Equitable	261,823	0	0	For
TIAA	261,525	0	0	For
MUTUAL FUND SERIES TRUST	231,685	0	0	For
Hartford	222,884	0	0	For
Jackson National	221,771	0	0	For
Manager Directed Portfolios	212,314	0	0	For
AB DISCOVERY GROWTH FUND, INC.	202,784	0	0	For
Brown Advisory Funds	201,802	0	0	For
John Hancock	194,000	0	0	For
Goldman Sachs	178,055	0	0	For
Brighthouse	158,646	0	17,858	For

Showing the 25 largest of 100 asset managers. See all 100 in the interactive database.

5. Election of Directors: Daniella Beckman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 54,014,668WITHHELD: 4,259,561

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Daniella Beckman”): 54,014,668 for, 4,259,561 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,616,902 outstanding shares: 86% for, 7% withheld (93% of the company cast a for/withheld vote).

The 99 asset managers below cast 100% of the shares they voted on this item FOR (32,353,509 for, 0 against).

FOR 94%

FOR: 32,353,509 (94.0%)ABSTAIN: 2,058,121 (6.0%)

Largest asset managers voting on “Election of Directors: Daniella Beckman” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	8,825,344	0	For
Fidelity	5,991,253	13,266	For
T. Rowe Price	5,448,322	0	For
BlackRock	3,279,222	0	For
Lord Abbett	1,145,420	0	For
Delaware/Macquarie	945,166	0	For
State Street	821,835	88	For
JPMorgan	724,726	0	For
American Century	519,467	0	For
Charles Schwab	0	502,210	Abstain
Invesco	430,463	0	For
AllianceBernstein	0	428,993	Abstain
WILLIAM BLAIR FUNDS	350,924	0	For
Principal	77,207	199,517	Abstain
Equitable	120,284	141,539	Abstain
TIAA	261,525	0	For
MUTUAL FUND SERIES TRUST	231,685	0	For
Hartford	222,884	0	For
Jackson National	221,771	0	For
Manager Directed Portfolios	0	212,314	Abstain
AB DISCOVERY GROWTH FUND, INC.	0	202,784	Abstain
Brown Advisory Funds	201,802	0	For
John Hancock	162,981	31,019	For
Goldman Sachs	178,055	0	For
Brighthouse	158,646	17,858	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

6. Election of Directors: Habib Dable

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD 30%

FOR: 40,783,723WITHHELD: 17,490,506

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Habib Dable”): 40,783,723 for, 17,490,506 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,616,902 outstanding shares: 65% for, 28% withheld (93% of the company cast a for/withheld vote).

The 99 asset managers below cast 99.9% of the shares they voted on this item FOR (26,810,163 for, 33 against).

FOR 78%ABSTAIN 22%

FOR: 26,810,163 (77.9%)AGAINST: 33 (0.0%)ABSTAIN: 7,601,434 (22.1%)

Largest asset managers voting on “Election of Directors: Habib Dable” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	8,825,344	0	For
Fidelity	5,991,253	13,266	For
T. Rowe Price	5,448,322	0	For
BlackRock	3,279,222	0	For
Lord Abbett	0	1,145,420	Abstain
Delaware/Macquarie	0	945,166	Abstain
State Street	870	821,053	Abstain
JPMorgan	724,726	0	For
American Century	0	519,467	Abstain
Charles Schwab	502,210	0	For
Invesco	0	430,463	Abstain
AllianceBernstein	0	428,993	Abstain
WILLIAM BLAIR FUNDS	0	350,924	Abstain
Principal	458	276,266	Abstain
Equitable	120,284	141,539	Abstain
TIAA	261,525	0	For
MUTUAL FUND SERIES TRUST	231,685	0	For
Hartford	222,884	0	For
Jackson National	0	221,771	Abstain
Manager Directed Portfolios	212,314	0	For
AB DISCOVERY GROWTH FUND, INC.	0	202,784	Abstain
Brown Advisory Funds	0	201,802	Abstain
John Hancock	109,582	84,418	For
Goldman Sachs	0	178,055	Abstain
Brighthouse	37,202	139,302	Abstain

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

7. Election of Directors: Lynn Seely

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD 27%

FOR: 42,706,299WITHHELD: 15,567,930

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Lynn Seely, M.D.”): 42,706,299 for, 15,567,930 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,616,902 outstanding shares: 68% for, 25% withheld (93% of the company cast a for/withheld vote).

The 99 asset managers below cast 99.9% of the shares they voted on this item FOR (27,682,317 for, 33 against).

FOR 80%ABSTAIN 20%

FOR: 27,682,317 (80.4%)AGAINST: 33 (0.0%)ABSTAIN: 6,729,280 (19.6%)

Largest asset managers voting on “Election of Directors: Lynn Seely” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	8,825,344	0	For
Fidelity	5,991,253	13,266	For
T. Rowe Price	5,448,322	0	For
BlackRock	3,279,222	0	For
Lord Abbett	0	1,145,420	Abstain
Delaware/Macquarie	0	945,166	Abstain
State Street	820,774	1,149	For
JPMorgan	724,726	0	For
American Century	0	519,467	Abstain
Charles Schwab	502,210	0	For
Invesco	0	430,463	Abstain
AllianceBernstein	0	428,993	Abstain
WILLIAM BLAIR FUNDS	0	350,924	Abstain
Principal	458	276,266	Abstain
Equitable	120,284	141,539	Abstain
TIAA	261,525	0	For
MUTUAL FUND SERIES TRUST	231,685	0	For
Hartford	222,884	0	For
Jackson National	0	221,771	Abstain
Manager Directed Portfolios	212,314	0	For
AB DISCOVERY GROWTH FUND, INC.	0	202,784	Abstain
Brown Advisory Funds	0	201,802	Abstain
John Hancock	109,582	84,418	For
Goldman Sachs	0	178,055	Abstain
Brighthouse	37,202	139,302	Abstain

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

8. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

ONE YEAR 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR: 1,136,017 (100.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
JPMorgan	0	0	0	0	One Year
Desjardins Global Asset Management Inc.	0	0	0	0	One Year
EFG Asset Management (North America) Corp.	0	0	0	0	One Year
Two Roads Shared Trust	0	0	0	0	One Year

9. Approval of a non-binding advisory vote on the frequency of future advisory votes on the H paid to our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 85%ONE YEAR 15%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (231,685 for, 0 against).

FOR: 231,685 (84.6%)ONE YEAR: 42,271 (15.4%)

Largest asset managers voting on “Approval of a non-binding advisory vote on the frequency of future advisory votes on the H paid to our named e” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
MUTUAL FUND SERIES TRUST	231,685	0	0	0	For
Segall Bryant & Hamill Trust	0	0	0	0	One Year

Largest BLUEPRINT MEDICINES CORP. shareholders voting in 2023-2024

Ranked by the number of BLUEPRINT MEDICINES CORP. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 62,616,902 shares outstanding at the time of that meeting.

Top BLUEPRINT MEDICINES CORP. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	T. Rowe Price	19.89%
2	Fidelity	17.78%
3	Vanguard	14.37%
4	BlackRock	8.62%
5	Wellington	6.17%
6	Man Group plc	4.79%
7	State Street	4.48%
8	Rock Springs Capital Management LP	3.99%
9	New York Life	3.33%
10	JPMorgan	2.93%

Reported BLUEPRINT MEDICINES CORP. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BLUEPRINT MEDICINES CORP. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
T. Rowe Price	9.98%	13F
The Vanguard Group	9.77%	13G
Wellington Management	6.67%	13F
State Street	3.50%	13F
Geode Capital	2.19%	13F
Invesco	1.29%	13F
Norges Bank	0.90%	13F
Northern Trust	0.89%	13F
Charles Schwab	0.80%	13F
D.E. Shaw	0.61%	13F

Percentages above are of 62,616,902 shares outstanding, as reported by BLUEPRINT MEDICINES CORP. on its Form 10-Q dated 2024-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BLUEPRINT MEDICINES CORP.’s 10-Q dated 2024-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At BLUEPRINT MEDICINES CORP.'s shareholder meeting held 2024-06-12, in the 2023-2024 proxy season, 310 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,417 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: BLUEPRINT MEDICINES CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-14.

BLUEPRINT MEDICINES CORP. proxy season coverage: 2023-2024 (this page) · 2024-2025.